This document discusses various drugs that can cause ototoxicity or damage to the inner ear. It notes that aminoglycoside antibiotics are the most common cause when administered systemically but topical drops are FDA approved. Other potentially ototoxic drugs mentioned include macrolides, antineoplastic agents, loop diuretics, salicylates, gentamicin, tobramycin, amikacin, erythromycin, cisplatin, furosemide, aspirin, and vancomycin when combined with aminoglycosides. The document also briefly discusses genetics, mechanisms of toxicity involving free radicals, and potential prevention with iron chelators and antioxidants like vitamin E.
This document discusses various drugs that can cause ototoxicity or damage to the inner ear. It notes that aminoglycoside antibiotics are the most common cause when administered systemically but topical drops are FDA approved. Other potentially ototoxic drugs mentioned include macrolides, antineoplastic agents, loop diuretics, salicylates, gentamicin, tobramycin, amikacin, erythromycin, cisplatin, furosemide, aspirin, and vancomycin when combined with aminoglycosides. The document also briefly discusses genetics, mechanisms of toxicity involving free radicals, and potential prevention with iron chelators and antioxidants like vitamin E.
This document discusses various drugs that can cause ototoxicity or damage to the inner ear. It notes that aminoglycoside antibiotics are the most common cause when administered systemically but topical drops are FDA approved. Other potentially ototoxic drugs mentioned include macrolides, antineoplastic agents, loop diuretics, salicylates, gentamicin, tobramycin, amikacin, erythromycin, cisplatin, furosemide, aspirin, and vancomycin when combined with aminoglycosides. The document also briefly discusses genetics, mechanisms of toxicity involving free radicals, and potential prevention with iron chelators and antioxidants like vitamin E.
• Systemic administration of Aminoglycosides cause both cochlear and vestibular toxicity • Aminoglycosides topical drops are noted FDA approved for use in the middle ear or open mastoid cavity Drugs with Ototoxicity • Aminoglycosides • Macrolides • Antineoplastic agents • Loop diuretics • Salicylates Gentamicin • 2~3% • Cupula semicircular canal – Type I hair cell loss • Cochlear – Outer hair cell damage Genetics of Ototoxicity • Mutation of mitochondrial DNA associated with hearing disorder Tobromycin • 3~4%, vestibular loss • 6%, cochlear loss Amikacin • 14%, cochlear loss
• Neomycin and kanamycin with high
incidence of cochlear loss Erythromycin • Transient cochlear loss • Rarely permanent loss • Dose related Cisplatin • 12~25%, cochlear loss – Cochlear hair cell loss – Degeneration of stria vascularis – Decrease in ganglion cells • Dose related Furosemide • < 1% • Transient loss • Abnormal stria vascularis Aspirin • Only transient hearing loss and tinnitus in doses over 2700mg/day Vancomycin • Rare cochlear loss • Become ototoxic combined with aminoglycosides Prevention • Iron chelator, deferoxime • Antioxidants • Vitamin E Mechanisms • Aminoglycosides, formation of iron complex, production of free radicals • Glutathione reduction secondary to free radicals production